By Kelly Cloonan

Shares of ClearPoint Neuro declined after the company logged a wider loss in 2025 and detailed a two-pronged growth strategy for the year ahead.

The stock fell 13% to $9.66 on Wednesday. Shares have slid 27% in the past year.

For 2025, ClearPoint posted a loss of $25.5 million, or 90 cents a share, compared with a loss of $18.9 million, or 70 cents a share, a year earlier.

Revenue rose 18% to $37 million, driven by higher product revenue.

For the full year, the company is guiding for revenue of $52 million to $56 million.

The company said it is focused on expanding its reach within pre-commercial drug-delivery products and services, neurosurgery navigation and robotics, laser therapy and neurocritical fluid management. The company expects all four product lines to grow in the double digits this year.

It is also working to build out a commercial cell and gene therapy delivery business including brain segmentation tools, predictive drug-delivery modeling and robotic delivery options, the ClearPoint said.

"Our company has never been in a stronger position than we are right now," Chief Executive Joe Burnett said.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

March 18, 2026 12:57 ET (16:57 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.